Efficacy and safety of tirofiban for acute ischemic stroke without large and medium vessel occlusion: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Efficacy and safety of tirofiban for acute ischemic stroke without large and medium vessel occlusion: a systematic review and meta-analysis
To assess the efficacy and safety of tirofiban in patients with non-LVO/MVO acute ischemic stroke and explore the influence of intravenous thrombolysis (IVT) status and study design on treatment outcomes.
Key Findings:
Tirofiban significantly increased the likelihood of achieving a 90-day excellent functional outcome (OR 1.66) and favorable functional outcome (OR 1.79).
No significant increase in risk of sICH (OR 4.02) or 90-day mortality (OR 1.06) associated with tirofiban.
Tirofiban was linked to a higher risk of peripheral bleeding (OR 1.87).
Functional benefits of tirofiban were significant in non-IVT patients but not in those with prior IVT.
Interpretation:
Tirofiban improves functional outcomes in non-LVO/MVO AIS patients, particularly those without prior IVT, while not increasing severe bleeding or mortality risks, though peripheral bleeding requires monitoring.
Limitations:
Inconsistencies in existing studies regarding tirofiban's efficacy and safety.
Limited high-quality evidence from large-scale pooled analyses.
Conclusion:
Tirofiban is effective in enhancing 90-day functional outcomes in non-LVO/MVO AIS, especially in patients without prior IVT, but its clinical utility post-IVT remains unproven.
Sentara Northern Virginia Medical Center has received the American Heart Association/American Stroke Association’s Get With The Guidelines® Target: Stroke Honor Roll Elite Plus Gold Plus Quality Achievement Award.
